LG

Longeveron IncNASDAQ LGVN Stock Report

Last reporting period 30 Jun, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

0.028

Micro

Exchange

XNAS - Nasdaq

LGVN Stock Analysis

LG

Uncovered

Longeveron Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

8/100

Low score

Market cap $B

0.028

Dividend yield

Shares outstanding

20.948 B

Longeveron, Inc. is a clinical stage biotechnology company. The company is headquartered in Miami, Florida and currently employs 19 full-time employees. The company went IPO on 2021-02-12. The firm's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The company is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The company is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The firm has completed two multicenter trials in the United States for aging frailty.

View Section: Eyestock Rating